LONDON, March 27, 2012 -- Race Ace Jordan Announces 'J1' Marketing and HospitalityFormula One legend, Eddie Jordan has today announced the launch of J1 - a new venture creating innovative marketing, hospitality and lifestyle opportunities.Jordan aims to use his profile and unrivalled industry contacts to bring the glitz and glamour of the Formula One lifestyle to a wider audience. J1 will specialize in 100% tailored packages delivering truly unique experiences at some of the world's biggest sport and entertainment events.Clients will be offered unique and custom designed corporate incentive hospitality packages with behind-the-scenes access and insight at events ranging from the Monte Carlo and Singapore GPs to backstage at the world's biggest rock concerts.J1 will seek to go beyond traditional hospitality and incentive offerings to create new prospects and opportunities for brands. Its independent and specialist sponsorship consultancy service will advise brands as to how they can create and establish a foothold within the sport and entertainment industry.J1 is the result of a partnership between Jordan and Murray Schwartz, founder of RPMC, which will combine Schwartz's market leading expertise in hospitality and sponsorship with the charisma and contacts that have made Jordan one of the most recognized faces in the industry. Schwartz boasts over 25 years experience delivering standout marketing solutions at events ranging from the Olympics to the Grammy's. Working with clients including McDonald's, Sony Ericsson and AB InBev. Schwartz's RPMC are specialists in delivering tailored programmes on the biggest stage.Eddie Jordan said: "I'm extremely excited to launch J1 as the latest Jordan brand. It will bring the excitement of Jordan Racing to hospitality and marketing by creating new and exclusive opportunities for brands."Murray Schwartz added: "I'm very much looking forward to working with someone as charismatic and dynamic as Eddie. We share the same passionate outlooks on life and business and we truly believe that J1 will redefine unique global hospitality experiences."RPMC (http://www.rpmc.com), a leading provider of global brand events and experiences, will be J1's official activation partner providing access to a worldwide network of entertainment, music, sports and travel partners.
Tuesday, March 27, 2012
AstraZeneca: Crestor Delivers Latest LDL-C Targets in High-Risk Patients at Lower Doses than Other Statins
Crestor Delivers Latest LDL-C Targets in High-Risk Patients at Lower Doses than Other Statins
LONDON, March 26, 2012 /PRNewswire/ --Results presented from new VOYAGER sub-analysisThis release is INTENDED EXCLUSIVELY FOR EUROPEAN mediaAstraZeneca today announced the results of a sub-analysis from the VOYAGER individual patient data meta-analysis, which suggests that achieving an LDL-C goal of <70 mg/dL or >50% reduction in LDL-C levels in patients at high risk requires aggressive statin therapy. These goals reflect the latest European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Guidelines for the Management of Dyslipidaemias. Results showed that a significantly greater percentage of patients achieved this goal with CRESTOR? (rosuvastatin) than with equal or double doses of atorvastatin (Lipitor®) or simvastatin. These findings were presented at the 2012 International Symposium on Atherosclerosis in Sydney, Australia.This sub-analysis was designed to determine the percentage of high-risk patients treated with rosuvastatin 10-40 mg, atorvastatin 10-80 mg or simvastatin 10-80 mg who achieved this recommended LDL-C goal. Additional findings from the VOYAGER sub-analysis included:Percentage of high-risk patients achieving LDL-C goal "These data reinforce CRESTOR as an important medication that helps get high-risk patients to recommended treatment targets" said Russ Esterline, VP Global Product Development Cardiovascular, As traZeneca. "Additionally, these favourable results add to the wealth of data that demonstrate CRESTOR is well positioned in the market to remain a statin of choice for physicians treating patients at increased-risk."Guidelines continue to stress the importance of achieving aggressive LDL-C treatment goals in higher risk patients and the important role of statins in achieving these goals. Under the recently updated ESC/EAS guidelines, target LDL-C goals have become more stringent, particularly for patients with established cardiovascular disease, type II diabetes and for other patients classified as being at very high risk of a primary or secondary cardiovascular event.The ESC/EAS guidelines recommend that clinicians should aim for LDL-C levels below <3.0 mmol/L (~115 mg/dL) in moderate risk patients, <2.5 mmol/L (~100 mg/dL) in high-risk patients and <1.8 mmol/L (~70 mg/dL) and/or at least 50 percent reduction in levels if this target cannot be reached in very high-risk patients.CRESTOR has been researched extensively for over 13 years, including 120 clinical trials of more than 67,000 patients worldwide from more than 55 countries.NOTES TO EDITORSCRESTOR has now received regulatory approvals in over 109 countries. Worldwide, doctors have written nearly 330 million prescriptions for CRESTOR.Data from clinical trials and real world use shows that the safety profile for
rosuvastatin is in line with that of other marketed statins.About AstraZenecaAstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
LONDON, March 26, 2012 /PRNewswire/ --Results presented from new VOYAGER sub-analysisThis release is INTENDED EXCLUSIVELY FOR EUROPEAN mediaAstraZeneca today announced the results of a sub-analysis from the VOYAGER individual patient data meta-analysis, which suggests that achieving an LDL-C goal of <70 mg/dL or >50% reduction in LDL-C levels in patients at high risk requires aggressive statin therapy. These goals reflect the latest European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Guidelines for the Management of Dyslipidaemias. Results showed that a significantly greater percentage of patients achieved this goal with CRESTOR? (rosuvastatin) than with equal or double doses of atorvastatin (Lipitor®) or simvastatin. These findings were presented at the 2012 International Symposium on Atherosclerosis in Sydney, Australia.This sub-analysis was designed to determine the percentage of high-risk patients treated with rosuvastatin 10-40 mg, atorvastatin 10-80 mg or simvastatin 10-80 mg who achieved this recommended LDL-C goal. Additional findings from the VOYAGER sub-analysis included:Percentage of high-risk patients achieving LDL-C goal "These data reinforce CRESTOR as an important medication that helps get high-risk patients to recommended treatment targets" said Russ Esterline, VP Global Product Development Cardiovascular, As traZeneca. "Additionally, these favourable results add to the wealth of data that demonstrate CRESTOR is well positioned in the market to remain a statin of choice for physicians treating patients at increased-risk."Guidelines continue to stress the importance of achieving aggressive LDL-C treatment goals in higher risk patients and the important role of statins in achieving these goals. Under the recently updated ESC/EAS guidelines, target LDL-C goals have become more stringent, particularly for patients with established cardiovascular disease, type II diabetes and for other patients classified as being at very high risk of a primary or secondary cardiovascular event.The ESC/EAS guidelines recommend that clinicians should aim for LDL-C levels below <3.0 mmol/L (~115 mg/dL) in moderate risk patients, <2.5 mmol/L (~100 mg/dL) in high-risk patients and <1.8 mmol/L (~70 mg/dL) and/or at least 50 percent reduction in levels if this target cannot be reached in very high-risk patients.CRESTOR has been researched extensively for over 13 years, including 120 clinical trials of more than 67,000 patients worldwide from more than 55 countries.NOTES TO EDITORSCRESTOR has now received regulatory approvals in over 109 countries. Worldwide, doctors have written nearly 330 million prescriptions for CRESTOR.Data from clinical trials and real world use shows that the safety profile for
rosuvastatin is in line with that of other marketed statins.About AstraZenecaAstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
L'Oreal-UNESCO Pour les Femmes et la Science:
The 14th Annual L'Oréal-Unesco Awards or Women on Science: From March 26 to March 29, Paris Welcomes and Honours Tomorrow's Scientific Talents
PARIS, March 26, 2012 /PRNewswire/ --The L'ORÉAL-UNESCO For Women in Science program is welcoming the 15 International Fellows in Paris for a week of scientific meetings and debates.There, you will also find photos and video portraits of the Fellows.BOALEDuring the Awards Ceremony taking place on March 29 at the UNESCO Headquarters, each Laureate, being an outstanding role model for the next generation of scientists, will receive an award from Irina Bokova, Director-General of UNESCO and Sir Lindsay Owen-Jones, Chairman of the L'Oréal Foundation in recognition of her contribution to the advancement of science.
---------------
About the L'Oréal FoundationThe L'Oréal Foundation, created in 2007, pursues the goal of making the world a better place each day. It draws on the Group's values and business to strengthen and perpetuate the Group's commitment to social responsibility. As the second-largest corporate foundation in France, the L'Oréal Foundation is committed to three types of action: promoting scientific research in the fundamental and human sciences, supporting education and helping individuals made vulnerable by alternations to their appearance to reclaim their rightful place in society.About UNESCOSince its creation in 1945, UNESCO has pursued its mission of promoting science at the service of sustainable development and peace. It focuses on policy devel
opment and building capacities in science, technology and innovation and promoting and strengthening science education and engineering. UNESCO fosters the sustainable management of freshwater, oceans and terrestrial resources, the protection of biodiversity, and using the power of science to cope with climate change and natural hazards. The Organization also works to eliminate all forms of discrimination and to promote equality between men and women, especially in scientific research.
PARIS, March 26, 2012 /PRNewswire/ --The L'ORÉAL-UNESCO For Women in Science program is welcoming the 15 International Fellows in Paris for a week of scientific meetings and debates.There, you will also find photos and video portraits of the Fellows.BOALEDuring the Awards Ceremony taking place on March 29 at the UNESCO Headquarters, each Laureate, being an outstanding role model for the next generation of scientists, will receive an award from Irina Bokova, Director-General of UNESCO and Sir Lindsay Owen-Jones, Chairman of the L'Oréal Foundation in recognition of her contribution to the advancement of science.
---------------
About the L'Oréal FoundationThe L'Oréal Foundation, created in 2007, pursues the goal of making the world a better place each day. It draws on the Group's values and business to strengthen and perpetuate the Group's commitment to social responsibility. As the second-largest corporate foundation in France, the L'Oréal Foundation is committed to three types of action: promoting scientific research in the fundamental and human sciences, supporting education and helping individuals made vulnerable by alternations to their appearance to reclaim their rightful place in society.About UNESCOSince its creation in 1945, UNESCO has pursued its mission of promoting science at the service of sustainable development and peace. It focuses on policy devel
opment and building capacities in science, technology and innovation and promoting and strengthening science education and engineering. UNESCO fosters the sustainable management of freshwater, oceans and terrestrial resources, the protection of biodiversity, and using the power of science to cope with climate change and natural hazards. The Organization also works to eliminate all forms of discrimination and to promote equality between men and women, especially in scientific research.
Sanofi and Regeneron Report Phase 2 Data for Potential First-in-Class Lipid-Lowering PCSK9 Antibody
Sanofi and Regeneron Report Phase 2 Data for Potential First-in-Class Lipid-Lowering PCSK9 Antibody
PARIS and TARRYTOWN, New York, March 26, 2012 /PRNewswire/ --- New Data Presented at American College of Cardiology Meeting Demonstrate Reductions of 40% to 72% in LDL-Cholesterol in Patients on Statins -Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that data from two Phase 2 trials with SAR236553/REGN727, an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), were presented at the American College of Cardiology's (ACC) 61st Annual Scientific Meeting in Chicago.To view the multimedia assets associated with this release, please click: http://www.multivu.com/mnr/55299-sanofi-regeneron-pharmaceuticals-lipid-lowering-medications-pcsk9-antibodyThe data showed that treatment with SAR236553/REGN727 over 8 to 12 weeks significantly reduced mean low-density lipoprotein-cholesterol (LDL-C, or "bad" cholesterol) by 40% to 72% in patients with elevated LDL-C on stable dose of statins.(1),(2)Presented today in a late-breaking clinical trials session at the ACC meeting, "Study DFI11565," the Phase 2 dose-finding clinical trial enrolled 183 patients with elevated LDL-C (greater than or equal to 100 mg/dL) despite being on a stable dose of atorvastatin. The objective of the study was to evaluate the effect of adding SAR23655
3/REGN727 to existing statin therapy. Across the five different dose regimens tested, patients receiving SAR236553/REGN727 for 12 weeks achieved and sustained a mean LDL-C reduction from baseline of 40% to 72%, compared to 5% in patients receiving placebo (p<0.0001). Patients in the study were followed for a total of 20 weeks for safety.The most common adverse events (AEs) with SAR236553/REGN727 were injection site reactions. Serious AEs occurred in one patient receiving placebo and three patients in the active treatment arms, including a patient on active treatment who experienced a skin rash diagnosed as leukocytoclastic vasculitis. Six patients, all on active treatment, prematurely discontinued therapy due to AEs. Muscle complaints were infrequent and similar across all treatment groups. There were no significant elevations in liver enzymes or other lab values in patients on active treatment.The PCSK9 mechanism is an example of how the study of genetics can identify new targets for developing new therapies.(3),(4) The role of PCSK9 in lipid metabolism was discovered a few years ago based on population studies.(5)Data from a separate trial, "Study DFI11566," were presented yesterday during an oral session of the ACC meeting. The study enrolled patients with primary hypercholesterolemia with elevated LDL-C (greater than or equal to 100 mg/dL) who were on a stable low dose of atorvastatin (10 mg). The primary objective of the study was to compare the effect on LDL-C lowering of switching to a high dose of atorvastatin alone (80 mg) versus a high dose of atorvastatin combined with SAR236553/REGN727. Patients who received SAR236553/REGN727 plus atorvastatin 80 mg achieved a mean reduction of 73% in LDL-C, compared to a mean reduction of 17% for patients who switched to atorvastatin 80 mg alone (p<0.001) after eight weeks. The study also included a third arm in which SAR236553/REGN727 was added to the stable low dose of atorvastatin. Patients in this arm achieved a 66% reduction in mean LDL-C. Patients in the study were followed for a total of 16 weeks for safety.In this trial, the most common AE with SAR236553/REGN727 was infection. There was one serious AE in the SAR236553/REGN727 plus atorvastatin 80 mg group (dehydration) that was deemed not to be treatment-related.A long-term safety and tolerability study of SAR236553/REGN727 (NCT01507831) is ongoing in patients with hypercholesterolemia who are not adequately controlled with their current lipid-modifying therapy.(6) Sanofi and Regeneron are intending to initiate Phase 3 clinical studies for SAR236553/REGN727 in Q2 2012.Sanofi and Regeneron are co-developing SAR236553/REGN727 as part of their research and development collaboration agreements.About PCSK9PCSK9 is known to be a determinant of circulating LDL levels, as it binds to LDL receptors resulting in their degradation so that fewer are available on liver cells to remove excess LDL-cholesterol from the blood. Moreover, traditional LDL-lowering therapies such as statins actually stimulate the production of PCSK9, which limits their own ability to lower LDL-cholesterol. Blocking the PCSK9 pathway is therefore a potentially novel mechanism for lowering LDL-cholesterol.SAR236553/REGN727 is a fully human monoclonal antibody directed against PCSK9, administered via subcutaneous injection. By inhibiting PCSK9, a determinant of circulating LDL-cholesterol levels in the blood, SAR236553/REGN727 increases the number of free LDL receptors which can bind to circulating LDL and clear it from the bloodstream. SAR236553/REGN727 was created using Regeneron's pioneering VelocImmune® technology.About primary hypercholesterolemiaHypercholesterolemia, particularly an increase in LDL-C levels, is a major risk factor for the development of cardiovascular disease. LDL-C is identified as the primary target of cholesterol-lowering therapies such as statins, which have significantly helped in managing the risk for cardiovascular disease.(7) However, despite the availability of statins, many patients with hypercholesterolemia are not reaching their recommended LDL-C goal and need new additional therapy.About SanofiSanofi, a global and
diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).About Regeneron Pharmaceuticals, Inc.Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets two products in the United States, one for the treatment of neovascular (wet) age-related macular degeneration and another for the treatment of a rare inflammatory condition. Additionally, Regeneron has three regulatory applications pending before the U.S. Food and Drug Administration (FDA) and 10 drug candidates in clinical development. More information and recent news releases are available on the Regeneron web site at http://www.regeneron.com/.Sanofi Forward Looking StatementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2011. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.Regeneron Forward-Looking StatementsThis news release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron, and actual events or results may differ materially from these forward-looking statements. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of Regeneron's product candidates and research and clinical programs now underway or planned, including without limitation SAR236553/REGN727, unforeseen safety issues resulting from the administration of products and product candidates in patients, the likelihood and timing of possible regulatory approval and commercial launch of Regeneron's late-stage product candidates, determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize Regeneron's product and drug candidates, competing drugs that may be superior to Regeneron's product and drug candidates, uncertainty of market acceptance of Regeneron's product and drug candidates, unanticipated expenses, the availability and cost of capital, the costs of developing, producing, and selling products, the potential for any license or collaboration agreement, including Regeneron's agreements with the Sanofi Group and Bayer HealthCare, to be canceled or terminated without any product success, and risks associated with third party intellectual property and pending or future litigation relating thereto. A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2011. Regeneron does not undertake any obligation to update publicly any forward-looking statement, whether as a result of new info
rmation, future events, or otherwise, unless required by law.
PARIS and TARRYTOWN, New York, March 26, 2012 /PRNewswire/ --- New Data Presented at American College of Cardiology Meeting Demonstrate Reductions of 40% to 72% in LDL-Cholesterol in Patients on Statins -Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that data from two Phase 2 trials with SAR236553/REGN727, an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), were presented at the American College of Cardiology's (ACC) 61st Annual Scientific Meeting in Chicago.To view the multimedia assets associated with this release, please click: http://www.multivu.com/mnr/55299-sanofi-regeneron-pharmaceuticals-lipid-lowering-medications-pcsk9-antibodyThe data showed that treatment with SAR236553/REGN727 over 8 to 12 weeks significantly reduced mean low-density lipoprotein-cholesterol (LDL-C, or "bad" cholesterol) by 40% to 72% in patients with elevated LDL-C on stable dose of statins.(1),(2)Presented today in a late-breaking clinical trials session at the ACC meeting, "Study DFI11565," the Phase 2 dose-finding clinical trial enrolled 183 patients with elevated LDL-C (greater than or equal to 100 mg/dL) despite being on a stable dose of atorvastatin. The objective of the study was to evaluate the effect of adding SAR23655
3/REGN727 to existing statin therapy. Across the five different dose regimens tested, patients receiving SAR236553/REGN727 for 12 weeks achieved and sustained a mean LDL-C reduction from baseline of 40% to 72%, compared to 5% in patients receiving placebo (p<0.0001). Patients in the study were followed for a total of 20 weeks for safety.The most common adverse events (AEs) with SAR236553/REGN727 were injection site reactions. Serious AEs occurred in one patient receiving placebo and three patients in the active treatment arms, including a patient on active treatment who experienced a skin rash diagnosed as leukocytoclastic vasculitis. Six patients, all on active treatment, prematurely discontinued therapy due to AEs. Muscle complaints were infrequent and similar across all treatment groups. There were no significant elevations in liver enzymes or other lab values in patients on active treatment.The PCSK9 mechanism is an example of how the study of genetics can identify new targets for developing new therapies.(3),(4) The role of PCSK9 in lipid metabolism was discovered a few years ago based on population studies.(5)Data from a separate trial, "Study DFI11566," were presented yesterday during an oral session of the ACC meeting. The study enrolled patients with primary hypercholesterolemia with elevated LDL-C (greater than or equal to 100 mg/dL) who were on a stable low dose of atorvastatin (10 mg). The primary objective of the study was to compare the effect on LDL-C lowering of switching to a high dose of atorvastatin alone (80 mg) versus a high dose of atorvastatin combined with SAR236553/REGN727. Patients who received SAR236553/REGN727 plus atorvastatin 80 mg achieved a mean reduction of 73% in LDL-C, compared to a mean reduction of 17% for patients who switched to atorvastatin 80 mg alone (p<0.001) after eight weeks. The study also included a third arm in which SAR236553/REGN727 was added to the stable low dose of atorvastatin. Patients in this arm achieved a 66% reduction in mean LDL-C. Patients in the study were followed for a total of 16 weeks for safety.In this trial, the most common AE with SAR236553/REGN727 was infection. There was one serious AE in the SAR236553/REGN727 plus atorvastatin 80 mg group (dehydration) that was deemed not to be treatment-related.A long-term safety and tolerability study of SAR236553/REGN727 (NCT01507831) is ongoing in patients with hypercholesterolemia who are not adequately controlled with their current lipid-modifying therapy.(6) Sanofi and Regeneron are intending to initiate Phase 3 clinical studies for SAR236553/REGN727 in Q2 2012.Sanofi and Regeneron are co-developing SAR236553/REGN727 as part of their research and development collaboration agreements.About PCSK9PCSK9 is known to be a determinant of circulating LDL levels, as it binds to LDL receptors resulting in their degradation so that fewer are available on liver cells to remove excess LDL-cholesterol from the blood. Moreover, traditional LDL-lowering therapies such as statins actually stimulate the production of PCSK9, which limits their own ability to lower LDL-cholesterol. Blocking the PCSK9 pathway is therefore a potentially novel mechanism for lowering LDL-cholesterol.SAR236553/REGN727 is a fully human monoclonal antibody directed against PCSK9, administered via subcutaneous injection. By inhibiting PCSK9, a determinant of circulating LDL-cholesterol levels in the blood, SAR236553/REGN727 increases the number of free LDL receptors which can bind to circulating LDL and clear it from the bloodstream. SAR236553/REGN727 was created using Regeneron's pioneering VelocImmune® technology.About primary hypercholesterolemiaHypercholesterolemia, particularly an increase in LDL-C levels, is a major risk factor for the development of cardiovascular disease. LDL-C is identified as the primary target of cholesterol-lowering therapies such as statins, which have significantly helped in managing the risk for cardiovascular disease.(7) However, despite the availability of statins, many patients with hypercholesterolemia are not reaching their recommended LDL-C goal and need new additional therapy.About SanofiSanofi, a global and
diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).About Regeneron Pharmaceuticals, Inc.Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets two products in the United States, one for the treatment of neovascular (wet) age-related macular degeneration and another for the treatment of a rare inflammatory condition. Additionally, Regeneron has three regulatory applications pending before the U.S. Food and Drug Administration (FDA) and 10 drug candidates in clinical development. More information and recent news releases are available on the Regeneron web site at http://www.regeneron.com/.Sanofi Forward Looking StatementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2011. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.Regeneron Forward-Looking StatementsThis news release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron, and actual events or results may differ materially from these forward-looking statements. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of Regeneron's product candidates and research and clinical programs now underway or planned, including without limitation SAR236553/REGN727, unforeseen safety issues resulting from the administration of products and product candidates in patients, the likelihood and timing of possible regulatory approval and commercial launch of Regeneron's late-stage product candidates, determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize Regeneron's product and drug candidates, competing drugs that may be superior to Regeneron's product and drug candidates, uncertainty of market acceptance of Regeneron's product and drug candidates, unanticipated expenses, the availability and cost of capital, the costs of developing, producing, and selling products, the potential for any license or collaboration agreement, including Regeneron's agreements with the Sanofi Group and Bayer HealthCare, to be canceled or terminated without any product success, and risks associated with third party intellectual property and pending or future litigation relating thereto. A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2011. Regeneron does not undertake any obligation to update publicly any forward-looking statement, whether as a result of new info
rmation, future events, or otherwise, unless required by law.
LIDE: Rainforest Protection and Social and Environmental Added Value are Issues Discussed at the Global Sustainability Forum
LIDE: Rainforest Protection and Social and Environmental Added Value are Issues Discussed at the Global Sustainability Forum
MANAUS, Brazil, March 26, 2012 /PRNewswire/ --- At the closing of the event, a commitment was signed by LIDE to mobilize society towards legislation to ensure sustainable developmentSocial and environmental activist Bianca Jagger raised the issue of "Sustainable development and human rights" during the discussions at the 3rd Global Sustainability Forum in Manaus. She noted that Amazonia is an extraordinary treasure, home to many species, and that we have already lost a great many kilometers of the Amazon rainforest. Bianca expressed her support for investment in sustainable energy. "We cannot sacrifice present and future generations in the name of development."(Photo: http://www2.prnewswire.com.br/imgs/pub/2012-03-25/original/640.jpg)For his part, Almir Surui, Chief of the Paiter Surui People (Rondonia), spoke about "The green economy and the peoples of the rainforest," pointing out that "public and private policies do not reach the communities they are supposed to reach. Surui called upon businessmen to take part in the creation of a development model for Amazonia.Oskar Metsavaht, fashion designer and businessman, founder and president of the label Osklen, talked about "Sustainability and the desire industry." As he sees it, the people of Brazil need to improve their lives. "Brazil needs to develop economically, and it has vast space to become a developed country with a fair distribution of income in a sustainable manner." To Metsavaht, one obstacle is the lack of a branding plan. "Unless we have added value, we'll just continue to be commodity vendors, just talking about charity." "We must show that it is more interesting to buy sustainable products from Brazil than famous brands from the United States, made with cheap labor from China."
Astellas Files Regulatory Submission for EC905 - A New Fixed Dose Combination Treatment for Male LUTS
Astellas Pharma Europe Ltd.: Astellas Files Regulatory Submission for EC905 - A New Fixed Dose Combination Treatment for Male LUTS
STAINES, England, March 27, 2012 /PRNewswire/ --EC905 is a combination tablet containing solifenacin 6 mg and tamsulosin OCAS 0.4 mg. Astellas is seeking approval for this new fixed dose combination therapy to treat lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia, with storage symptoms.About Astellas Pharma Europe Ltd.:Astellas Pharma Europe Ltd., located in the UK, is the European headquarters of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceuticals. The organisation is committed to becoming a global company by combining outstanding R&D and marketing capabilities and continuing to grow in the world pharmaceutical market. Astellas Pharma Europe Ltd. is responsible for 21 affiliate offices located across Europe, the Middle East and Africa, an R&D site and three manufacturing plants. The company employs approximately 4,200 staff across these regions. For more information about Astellas Pharma Europe, please visit http://www.astellas.eu.
Otis Announces Six Contract Wins for the King Abdullah Financial District in Saudi Arabia
Otis Announces Six Contract Wins for the King Abdullah Financial District in Saudi Arabia
FARMINGTON, Connecticut, March 27, 2012 /PRNewswire/ --Otis Elevator Company Saudi Arabia Ltd., an affiliate of http://www.otisworldwide.com/, a unit of United Technologies Corp. (NYSE: UTX), today announced that it has won six contracts to supply and install 263 elevators, including 10 double-deck elevators, and 90 escalators to different buildings in the King Abdullah Financial District in Riyadh, Saudi Arabia. The King Abdullah Financial District is designed to be the world's first newly developed major financial district of the 21st century and represents the latest stage in a carefully planned and implemented program of financial modernization by Saudi Arabia."With these wins, Otis builds upon a heritage of leadership and innovation in Saudi Arabia," said Otis President Pedro Baranda. "We are honored to be a part of these structures and the world's newest financial center and look forward to a continued partnership with the Middle East's premier financial district."Two of the tallest structures in the District, the KAFD World Trade Centre and Gulf Cooperation Council (GCC) Bank Headquarters, the Gulf region's governing financial institution, will include Otis elevators and escalators. Otis will install 25 elevators and eight escalators in the KAFD World Trade Centre and 30 elevators and four escalators in the GCC Bank Headquarters.Otis double-deck elev
ators will play a critical role at both the KAFD World Trade Centre and GCC Bank Headquarters. Double-deck elevators save space in a building, allowing room that would otherwise be needed for elevator use to be used as rentable space. Depending on the building and its needs, double-deck elevators can save up to 40 percent of the space required by traditional elevators while increasing transportation capacity by up to 30 percent. In addition, Otis double-deck elevators enable building developers to create taller structures with a more limited ground-level footprint.At 300-meters tall, the KAFD World Trade Centre will include four amenity levels centered on the Otis double-deck elevators. It is scheduled to be completed in late 2012. At GCC Bank Headquarters, the building's functional and spatial arrangements have been carefully considered to support the business activities of its occupier. Three sky-lobbies, accessed by Otis double-deck elevators, will ensure amenity floors are easily reached from any of the tower's 53 stories.Otis products have been selected by other global trade and financial centers, including the http://www.otisworldwide.com/b4-newsarchdet.html?item=20041220 in China and both the http://www.otisworldwide.com/b4-newsarchdet.html?item=20110126 and http://www.otisworldwide.com/b4-newsarchdet.html?item=20030715 in lower Manhattan.About Otis Elevator CompanyOt
is Elevator Company is the world's largest manufacturer and maintainer of people-moving products including elevators, escalators and moving walkways. With headquarters in Farmington, Connecticut, Otis employs 60,000 people, offers products and services in more than 200 countries and territories and maintains over 1.8 million elevators and escalators worldwide. United Technologies Corp., based in Hartford, Connecticut, is a diversified company providing high technology products and services to the building and aerospace industries.
FARMINGTON, Connecticut, March 27, 2012 /PRNewswire/ --Otis Elevator Company Saudi Arabia Ltd., an affiliate of http://www.otisworldwide.com/, a unit of United Technologies Corp. (NYSE: UTX), today announced that it has won six contracts to supply and install 263 elevators, including 10 double-deck elevators, and 90 escalators to different buildings in the King Abdullah Financial District in Riyadh, Saudi Arabia. The King Abdullah Financial District is designed to be the world's first newly developed major financial district of the 21st century and represents the latest stage in a carefully planned and implemented program of financial modernization by Saudi Arabia."With these wins, Otis builds upon a heritage of leadership and innovation in Saudi Arabia," said Otis President Pedro Baranda. "We are honored to be a part of these structures and the world's newest financial center and look forward to a continued partnership with the Middle East's premier financial district."Two of the tallest structures in the District, the KAFD World Trade Centre and Gulf Cooperation Council (GCC) Bank Headquarters, the Gulf region's governing financial institution, will include Otis elevators and escalators. Otis will install 25 elevators and eight escalators in the KAFD World Trade Centre and 30 elevators and four escalators in the GCC Bank Headquarters.Otis double-deck elev
ators will play a critical role at both the KAFD World Trade Centre and GCC Bank Headquarters. Double-deck elevators save space in a building, allowing room that would otherwise be needed for elevator use to be used as rentable space. Depending on the building and its needs, double-deck elevators can save up to 40 percent of the space required by traditional elevators while increasing transportation capacity by up to 30 percent. In addition, Otis double-deck elevators enable building developers to create taller structures with a more limited ground-level footprint.At 300-meters tall, the KAFD World Trade Centre will include four amenity levels centered on the Otis double-deck elevators. It is scheduled to be completed in late 2012. At GCC Bank Headquarters, the building's functional and spatial arrangements have been carefully considered to support the business activities of its occupier. Three sky-lobbies, accessed by Otis double-deck elevators, will ensure amenity floors are easily reached from any of the tower's 53 stories.Otis products have been selected by other global trade and financial centers, including the http://www.otisworldwide.com/b4-newsarchdet.html?item=20041220 in China and both the http://www.otisworldwide.com/b4-newsarchdet.html?item=20110126 and http://www.otisworldwide.com/b4-newsarchdet.html?item=20030715 in lower Manhattan.About Otis Elevator CompanyOt
is Elevator Company is the world's largest manufacturer and maintainer of people-moving products including elevators, escalators and moving walkways. With headquarters in Farmington, Connecticut, Otis employs 60,000 people, offers products and services in more than 200 countries and territories and maintains over 1.8 million elevators and escalators worldwide. United Technologies Corp., based in Hartford, Connecticut, is a diversified company providing high technology products and services to the building and aerospace industries.
Bjorn Borg AB: Time for Earth Hour and Turning the Lights Off, But What Happens in the Dark?
Bjorn Borg AB: Time for Earth Hour and Turning the Lights Off, But What Happens in the Dark?
STOCKHOLM, March 27, 2012 /PRNewswire/ --Björn Borg Figured it All Out in a Recent SurveyWhile Spaniards are most likely to get sexy in the dark, Germans and Swedes watch TV and the Dutch relax in front of the fireplace. These are some of the conclusions that can be drawn from the lights off survey.(Photo : http://www.newscom.com/cgi-bin/prnh/20120327/521016-a)(Photo : http://www.newscom.com/cgi-bin/prnh/20120327/521016-b)The survey also sheds some light on whether we prefer having our lights on or off for a roll in the hay. Spaniards and Germans like what they see and prefer keeping the lights on, while a majority of the people from other countries prefer the lights off. Most likely to turn their lights off while doing it are people in the UK, US and Sweden. Being ecological while burning some human energy is sexy!So what's the charm with the dark? Do we dare to get more naughty? Yeah baby, yeah - if you live in the US, China or France. But the reasons may not be as sexy as that. Sadly as many as 1/5 of all Swedes, Americans and Germans prefer lights off due to lack of self-confidence. And in China almost 1/5 of the male respondents turn their lights off in order to think of someone else.What will help you having a better time in the dark? Tools and gadgets are popular among couples and in particular among Germans, Spaniards and the Chinese. In Spain and Ita
ly mirrors are particularly popular in the dark - nothing reveals how they would see anything in the dark though? Last but not least, ¼ of the respondents mention that GLOW IN THE DARK underwear would help them having a good time in the dark - especially in China (33%), France (30%) and the US (30%).Best of voxpops, downloadable from: http://www.vimeo.com/bjornborgAll voxpops, for viewing at: http://www.youtube.com/bjornborglightsoffThe Group owns the Björn Borg trademark and its core business is underwear. It also offers clothes, footwear, bags, eyewear and fragrances through licensees. Björn Borg products are sold in around twenty markets, of which Sweden and the Netherlands are the largest. The Björn Borg Group has operations at every level from branding to consumer sales in its own Björn Borg stores. Total sales of Björn Borg products in 2011 amounted to almost SEK 1.7 billion, excluding VAT, at the consumer level. Group net sales amounted to SEK 537 million as per December 31, 2011, with 131 employees. The Björn Borg share has been listed on NASDAQ OMX Nordic in Stockholm since 2007.
STOCKHOLM, March 27, 2012 /PRNewswire/ --Björn Borg Figured it All Out in a Recent SurveyWhile Spaniards are most likely to get sexy in the dark, Germans and Swedes watch TV and the Dutch relax in front of the fireplace. These are some of the conclusions that can be drawn from the lights off survey.(Photo : http://www.newscom.com/cgi-bin/prnh/20120327/521016-a)(Photo : http://www.newscom.com/cgi-bin/prnh/20120327/521016-b)The survey also sheds some light on whether we prefer having our lights on or off for a roll in the hay. Spaniards and Germans like what they see and prefer keeping the lights on, while a majority of the people from other countries prefer the lights off. Most likely to turn their lights off while doing it are people in the UK, US and Sweden. Being ecological while burning some human energy is sexy!So what's the charm with the dark? Do we dare to get more naughty? Yeah baby, yeah - if you live in the US, China or France. But the reasons may not be as sexy as that. Sadly as many as 1/5 of all Swedes, Americans and Germans prefer lights off due to lack of self-confidence. And in China almost 1/5 of the male respondents turn their lights off in order to think of someone else.What will help you having a better time in the dark? Tools and gadgets are popular among couples and in particular among Germans, Spaniards and the Chinese. In Spain and Ita
ly mirrors are particularly popular in the dark - nothing reveals how they would see anything in the dark though? Last but not least, ¼ of the respondents mention that GLOW IN THE DARK underwear would help them having a good time in the dark - especially in China (33%), France (30%) and the US (30%).Best of voxpops, downloadable from: http://www.vimeo.com/bjornborgAll voxpops, for viewing at: http://www.youtube.com/bjornborglightsoffThe Group owns the Björn Borg trademark and its core business is underwear. It also offers clothes, footwear, bags, eyewear and fragrances through licensees. Björn Borg products are sold in around twenty markets, of which Sweden and the Netherlands are the largest. The Björn Borg Group has operations at every level from branding to consumer sales in its own Björn Borg stores. Total sales of Björn Borg products in 2011 amounted to almost SEK 1.7 billion, excluding VAT, at the consumer level. Group net sales amounted to SEK 537 million as per December 31, 2011, with 131 employees. The Björn Borg share has been listed on NASDAQ OMX Nordic in Stockholm since 2007.
Monday, March 26, 2012
con preghiera di divulgazione: INVERSO in concerto al Felt Music Club di Roma
link di riferimento: http://www.feltmusic.it/index.php/inverso-in-concerto/
------------------------------------------
"una strana luce accesa"
Tra le calde note latineggianti del tango, tra le sensuali dissonanze arabe, tra le romantiche atmosfere della fisarmonica francese, tra le melodie tradizionali italiane, in una sinestetica alchimia in cui le frequenze e lunghezza d'onda si trasformano e la musica diventa per malia "una strana luce accesa"
Carlo Picone – voce chitarra e pianoforte
Rocco Ciucci – fisarmonica
Vincenzo Picone - basso
Marina – violoncello
Fabrizio Verduchi – percussioni
Mauro Fiore – batteria
Dino Picone – Trombone
Ore 21:30: Esposizione di quadri dell'artista Costanza Majorani
Ore 22:30: INVERSO in concerto: Una strana luce acesa.
INGRESSO LIBERO CON TESSERA. (Costo della tessera 5 euro)
Info e Contatti
Felt Music Club
via degli ausoni 84
tel 06491978
email: info@feltmusic.it
Un saluto dalla redazione di myPressLab
Visita la nostra pagina Facebook! www.facebook.com/socialmediaexpert.italia
Seguici su Twitter! www.twitter.com/mypresslab
skype: mypresslab
msn: mypresslab@live.it
mob. 345.160.29.94
www.mypresslab.com - the Social Media Expert
----------
Ai sensi del D.lgs n. 196 del 30.06.03 (Codice Privacy) si precisa che le informazioni contenute in questo messaggio sono riservate e ad uso esclusivo del destinatario. Qualora il messaggio in parola Le fosse pervenuto per errore, La preghiamo di eliminarlo senza copiarlo e di non inoltrarlo a terzi, dandocene gentilmente comunicazione. Grazie
This message, for the D.lgs n. 196/30.06.03 (Privacy Code), may contain confidential and/or privileged information. If you are not the addressee or authorized to receive this for the addressee, you must not use, copy, disclose or take any action based on this message or any information herein. If you have received this message in error, please advise the sender immediately by reply e-mail and delete this message. Thank you for your cooperation.
con preghiera di divulgazione: Il 28 Marzo torna la Primavera, torna Arte2o!
------------------------------
Il 28 Marzo torna la Primavera, torna Arte2o!
Arte2o "La più Classica delle alternative -
Tutto quello che non ti aspetteresti mai un mercoledì sera in un club".
Mercoledì 28 marzo ore 21.30
MARZO è: "GIOCHI DI LUCE"
Concerto
Quartetto Berio
Houman Vaziri, violino
Roberto Palma, violino
Arianna Bloise, viola
Jo-Chan Lin, violoncello
Musiche di Mendelssohn
Duo Nati-Ammendola
Gloria Ammendola, flauto
Flavio Nati, chitarra
Musiche di Carulli, Catelnuovo-Tedesco
Halftime special exhibition: Lucina De Martis con Alessio Renzopaoli
presenta L'ALTRA HAITI (danze, ritmi e canti rituali)
"GIOCHI DI LUCE" esposizione pittorica di Federica Marini
a cura di Giulia Marchioni
--
Un saluto dalla redazione di myPressLab
Visita la nostra pagina Facebook! www.facebook.com/socialmediaexpert.italia
Seguici su Twitter! www.twitter.com/mypresslab
skype: mypresslab
msn: mypresslab@live.it
mob. 345.160.29.94
www.mypresslab.com - the Social Media Expert
----------
Ai sensi del D.lgs n. 196 del 30.06.03 (Codice Privacy) si precisa che le informazioni contenute in questo messaggio sono riservate e ad uso esclusivo del destinatario. Qualora il messaggio in parola Le fosse pervenuto per errore, La preghiamo di eliminarlo senza copiarlo e di non inoltrarlo a terzi, dandocene gentilmente comunicazione. Grazie
This message, for the D.lgs n. 196/30.06.03 (Privacy Code), may contain confidential and/or privileged information. If you are not the addressee or authorized to receive this for the addressee, you must not use, copy, disclose or take any action based on this message or any information herein. If you have received this message in error, please advise the sender immediately by reply e-mail and delete this message. Thank you for your cooperation.
Microsoft Corp.: Online Advertising Startup Competes More Effectively, Spends Less on IT With Cloud-Based Windows Azure
Online Advertising Startup Competes More Effectively, Spends Less on IT With Cloud-Based Windows Azure
THE HAGUE, Netherlands, March 26, 2012 -- - Fast-growing Crumbtag adopts Windows Azure to meet its massive data-processing needs without buying costly IT infrastructure.To target its customers' online advertising efficiently, Netherlands-based startup Crumbtag has adopted Windows Azure, a cloud-based platform that provides the firm with cost-effective processing power and agile scalability. (Logo: http://photos.prnewswire.com/prnh/20000822/MSFTLOGO)Crumbtag had a novel idea for Internet ad placement that involved analyzing Web visitor behavior in real time, but this operation required massive data-processing capability. Since tapping into cloud services with the Windows Azure platform, the young company scales processing power and storage on demand, serves the needs of very large customers, and offers more competitive rates for online advertising."Because we are not spending millions on IT infrastructure, we can pass those savings on to customers," said Crumbtag Founder and CEO Jan Kopmels. "As a small startup, we've been able to compete successfully for multinational customers and also demonstrate to them that we use cutting-edge technology." Kopmels estimates that with the cloud-based Microsoft Corp. solution, Crumbtag has avoided a $10 million (U.S.) outlay for on-premises infrastructure.Typically, online advertising firms match ads to users' interests through the use of cookies, which are deposited covertly on a user's computer during website visits. Cookies help determine the user's online behavior, such as sites visited, paths to sites visited and shopping cart contents. However, privacy concerns have prompted many countries to outlaw them. From an advertiser's perspective, cookies have limited value because they cannot be stored centrally for analysis.Kopmels wanted to capture user behavior and process it in a giant statistical database. This would allow customers to place ads without relying on cookies and also adjust and refine their placements dynamically with every Web page view and click.With a small but committed team, Kopmels launched Crumbtag in 2009 and spent two years developing technology for the ad-placement application. He came to the discouraging realization that the tiny firm would have to spend millions on datacenter infrastructure to process the prodigious amounts of data involved. "We needed a whole new infrastructure and business model to make Crumbtag viable," he said.In December 2010, the company explored several market-leading cloud services. Because they'd developed the ad-placement application using the Microsoft .NET Framework and Microsoft SQL Server 2008 data management software, Crumbtag opted to go with the Microsoft cloud-based solution. "We looked briefly at Amazon cloud solutions
but felt they were too immature," Kopmels said. "Plus, we were a committed user of Microsoft technology."It took Crumbtag just six weeks to move the application to Windows Azure - about 20 minutes of which was required to migrate the database to SQL Azure. "For an experienced .NET developer, moving to Windows Azure is a piece of cake," Kopmels said.Crumbtag uses Windows Azure Compute to supply on-demand processing power for its application, which processes about 4,000 requests per second and provides a 20-millisecond response time to well-known Dutch companies ranging from small to multinational. Crumbtag also uses Windows Azure Caching to provide high-speed communication between virtual machines.As it pursues plans to expand across Europe in 2012, Crumbtag is using Windows Azure to scale up quickly to serve its growing customer base. Cloud computing enables the small company to offer a more cost-effective solution that helps it win business against larger, more established players that are saddled with aging on-premises IT setups.
THE HAGUE, Netherlands, March 26, 2012 -- - Fast-growing Crumbtag adopts Windows Azure to meet its massive data-processing needs without buying costly IT infrastructure.To target its customers' online advertising efficiently, Netherlands-based startup Crumbtag has adopted Windows Azure, a cloud-based platform that provides the firm with cost-effective processing power and agile scalability. (Logo: http://photos.prnewswire.com/prnh/20000822/MSFTLOGO)Crumbtag had a novel idea for Internet ad placement that involved analyzing Web visitor behavior in real time, but this operation required massive data-processing capability. Since tapping into cloud services with the Windows Azure platform, the young company scales processing power and storage on demand, serves the needs of very large customers, and offers more competitive rates for online advertising."Because we are not spending millions on IT infrastructure, we can pass those savings on to customers," said Crumbtag Founder and CEO Jan Kopmels. "As a small startup, we've been able to compete successfully for multinational customers and also demonstrate to them that we use cutting-edge technology." Kopmels estimates that with the cloud-based Microsoft Corp. solution, Crumbtag has avoided a $10 million (U.S.) outlay for on-premises infrastructure.Typically, online advertising firms match ads to users' interests through the use of cookies, which are deposited covertly on a user's computer during website visits. Cookies help determine the user's online behavior, such as sites visited, paths to sites visited and shopping cart contents. However, privacy concerns have prompted many countries to outlaw them. From an advertiser's perspective, cookies have limited value because they cannot be stored centrally for analysis.Kopmels wanted to capture user behavior and process it in a giant statistical database. This would allow customers to place ads without relying on cookies and also adjust and refine their placements dynamically with every Web page view and click.With a small but committed team, Kopmels launched Crumbtag in 2009 and spent two years developing technology for the ad-placement application. He came to the discouraging realization that the tiny firm would have to spend millions on datacenter infrastructure to process the prodigious amounts of data involved. "We needed a whole new infrastructure and business model to make Crumbtag viable," he said.In December 2010, the company explored several market-leading cloud services. Because they'd developed the ad-placement application using the Microsoft .NET Framework and Microsoft SQL Server 2008 data management software, Crumbtag opted to go with the Microsoft cloud-based solution. "We looked briefly at Amazon cloud solutions
but felt they were too immature," Kopmels said. "Plus, we were a committed user of Microsoft technology."It took Crumbtag just six weeks to move the application to Windows Azure - about 20 minutes of which was required to migrate the database to SQL Azure. "For an experienced .NET developer, moving to Windows Azure is a piece of cake," Kopmels said.Crumbtag uses Windows Azure Compute to supply on-demand processing power for its application, which processes about 4,000 requests per second and provides a 20-millisecond response time to well-known Dutch companies ranging from small to multinational. Crumbtag also uses Windows Azure Caching to provide high-speed communication between virtual machines.As it pursues plans to expand across Europe in 2012, Crumbtag is using Windows Azure to scale up quickly to serve its growing customer base. Cloud computing enables the small company to offer a more cost-effective solution that helps it win business against larger, more established players that are saddled with aging on-premises IT setups.
Study Published Today in The Lancet Infectious Diseases shows that DIFICLIR[TM] Offers Potential Benefits Over Current Standard of Care for Clostridium difficile Infection
Astellas Pharma Europe Ltd: Study Published Today in The Lancet Infectious Diseases shows that DIFICLIR[TM] Offers Potential Benefits Over Current Standard of Care for Clostridium difficile Infection
STAINES, England, March 26, 2012 /PRNewswire/ --Clostridium difficile infection (CDI), a potentially fatal disease, is one of the most common healthcare acquired infections in Europe"CDI is a significant and growing problem in hospitals and care homes. The high percentage of patients experiencing CDI recurrence remains one of the biggest barriers to improving the management of this severe and sometimes life-threatening condition", said Professor Oliver Cornely, Medical Director of the Clinical Trial Center of The University of Cologne, Germany and lead investigator of the study. "In this study, DIFICLIR significantly reduced disease recurrence compared to vancomycin, the current standard of care, showing real promise as an effective treatment alternative for patients with CDI.""There is a clear need for new treatment advances to reduce the impact of this distressing and widespread disease. The results of this study reinforce the strong data we have already seen for DIFICLIR and support its position as a new and exciting treatment option for CDI," said Ken Jones, President and CEO of Astellas Pharma Europe Ltd.*Please note: clinical cure was defined as the resolution of diarrhoea for the duration of treatment and no need for further CDI therapy two days after completion of study medication, as determined by the investigator.NOTES TO EDITORS:About Astellas Phar
ma EuropeAstellas Pharma Europe Ltd., located in the UK, is a European subsidiary of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceuticals. The organisation is committed to becoming a global company by combining outstanding R&D and marketing capabilities and continuing to grow in the world pharmaceutical market. Astellas Pharma Europe Ltd. is responsible for 21 affiliate offices located across Europe, the Middle East and Africa, an R&D site and three manufacturing plants. The company employs approximately 4,200 staff across these regions. For more information about Astellas Pharma Europe, please visit http://www.astellas.eu .
Microsoft and Nokia to Invest Up to 18 Million Euros in Mobile Application Development Program at Aalto University
HELSINKI, Finland, March 26, 2012 --- Mobile developers to benefit from funding, training, support and business opportunities as Microsoft and Nokia launch the AppCampus program at Aalto University.To drive innovation and business opportunities in Finland's mobile ecosystem and beyond, Microsoft Corp. and Nokia will each invest up to 9 million euros into a newly established mobile application development program at Aalto University during the next three years. The AppCampus program has been set up to foster the creation of innovative mobile applications for the Windows Phone ecosystem, and in addition Nokia platforms, including Symbian and Series 40, to create a new generation of self-sustaining mobile startups.(Logo: http://photos.prnewswire.com/prnh/20000822/MSFTLOGO)Kicking off in May 2012, the Finland-based program will be led and managed by Aalto University, which has a growing reputation as a hotbed of new startup companies. AppCampus is intended to attract thousands of application proposals from students and entrepreneurs from all over the world. Aalto University will make a significant contribution to the project by providing premises, coaching services, and access to both academic and business networks for budding app developers.Within the AppCampus program, mobile entrepreneurs can benefit from comprehensive support, training in mobile
technology, design and usability, and funding to create innovative new mobile apps and services. Windows Phone Marketplace and Nokia Store offer local and global business opportunities to program participants via distribution to consumers around the world.Mentored by veterans in the mobile industry, program participants will be given insights and business coaching to help them commercialize their ideas while retaining the full intellectual property rights for their innovations."The ICT industry and knowledge base in Finland is one of the most competitive in the world, particularly in the mobile technology field," said Jyrki Katainen, Finnish prime minister, at the launch event for the AppCampus program in Helsinki. "Finland is an early-adopter market, and the significance of national education and technology innovation is deeply rooted in our culture. As a result, there is a growing appetite for entrepreneurship among the younger generation at Aalto University and beyond. The partnership between Microsoft and Nokia is a critical investment in this growing ecosystem and represents an exciting opportunity and access to global markets for our local startup community.""AppCampus offers an unprecedented opportunity for entrepreneurs to put their ideas into practice and create world-class mobile products," said Klaus Holse, president, Microsoft Western Europe. "We want to turn a ne
w leaf in the mobile industry and foster Finland's role as a center of excellence for mobile technology. Such investment into early-stage concepts has rarely been seen in this sector, and this demonstrates how highly both Nokia and Microsoft value Finnish mobile expertise.""We are proud to announce this new program, which will enable new and existing developers to create next-generation mobile apps and unique user experiences," said Kai Oistamo, executive vice president, Nokia Corp. "The partnership will allow developers to ideate and monetize business opportunities globally, via both Windows Phone Marketplace and Nokia Store.""An essential part of Aalto University's mission is to strengthen Finland's competitiveness," said Tuula Teeri, president of Aalto University. "We are pleased to host this initiative, which concretely boosts utilization of new knowledge and skills in creation of new entrepreneurial ventures.""Through our technology transfer and Aalto Venture Garage activities, the Aalto University community has been able to help catalyze the creation and growth of more than 30 companies during the past two years, with a number of them having mobile applications," said Will Cardwell, head of the Aalto University Center for Entrepreneurship, which will be charged with managing the program. "The people and ideas we work with hail from all corners of the world, and our partn
ership with Microsoft and Nokia will further strengthen our global network. This program will provide a unique opportunity to turn application ideas into real business with the support of world-class partners and coaches.""Within our student community, we have a strong mission to boost entrepreneurship and to create more startups," said Teemu Tapanila, a board member of the Aalto Entrepreneurship Society and leader of the Windows Phone Aalto community. "We warmly welcome the opportunities and networks brought by this cooperation."On the AppCampus ProgramMobile entrepreneurs can apply for grants within the AppCampus program beginning in May 2012. More information can be found at http://appcampus.aalto.fi/.About NokiaNokia is a global leader in mobile communications whose products have become an integral part of the lives of people around the world. Every day, more than 1.3 billion people use their Nokia to capture and share experiences, access information, find their way or simply to speak to one another. Nokia's technological and design innovations have made its brand one of the most recognized in the world. For more information, visit http://www.nokia.com/about-nokia.About the Aalto University Center for EntrepreneurshipThe Aalto Center for Entrepreneurship (ACE) at Aalto University, Finland, offers innovation, commercialization, and start-up services for Aalto University res
earchers, students and other stakeholders. In addition, we facilitate innovation and growth entrepreneurship by co-creating research and education of these areas across all the Aalto schools. ACE partially funds and participates in the award-winning Aalto Venture Garage and Startup Sauna open source seed accelerator. For more information, visit http://www.aalto.fi/ and http://ace.aalto.fi/.About MicrosoftFounded in 1975, Microsoft (Nasdaq: MSFT) is the worldwide leader in software, services and solutions that help people and businesses realise their full potential.About Microsoft EMEA (Europe, Middle East and Africa)Microsoft has operated in EMEA since 1982. In the region Microsoft employs more than 16,000 people in over 64 subsidiaries, delivering products and services in more than 139 countries and territories.This material is for informational purposes only. Microsoft Corp disclaims all warranties and conditions with regard to use of the material for other purposes. Microsoft Corp shall not, at any time, be liable for any special, direct, indirect or consequential damages, whether in an action of contract, negligence or other action arising out of or in connection with the use or performance of the material. Nothing herein should be construed as constituting any kind of warranty.
w leaf in the mobile industry and foster Finland's role as a center of excellence for mobile technology. Such investment into early-stage concepts has rarely been seen in this sector, and this demonstrates how highly both Nokia and Microsoft value Finnish mobile expertise.""We are proud to announce this new program, which will enable new and existing developers to create next-generation mobile apps and unique user experiences," said Kai Oistamo, executive vice president, Nokia Corp. "The partnership will allow developers to ideate and monetize business opportunities globally, via both Windows Phone Marketplace and Nokia Store.""An essential part of Aalto University's mission is to strengthen Finland's competitiveness," said Tuula Teeri, president of Aalto University. "We are pleased to host this initiative, which concretely boosts utilization of new knowledge and skills in creation of new entrepreneurial ventures.""Through our technology transfer and Aalto Venture Garage activities, the Aalto University community has been able to help catalyze the creation and growth of more than 30 companies during the past two years, with a number of them having mobile applications," said Will Cardwell, head of the Aalto University Center for Entrepreneurship, which will be charged with managing the program. "The people and ideas we work with hail from all corners of the world, and our partn
ership with Microsoft and Nokia will further strengthen our global network. This program will provide a unique opportunity to turn application ideas into real business with the support of world-class partners and coaches.""Within our student community, we have a strong mission to boost entrepreneurship and to create more startups," said Teemu Tapanila, a board member of the Aalto Entrepreneurship Society and leader of the Windows Phone Aalto community. "We warmly welcome the opportunities and networks brought by this cooperation."On the AppCampus ProgramMobile entrepreneurs can apply for grants within the AppCampus program beginning in May 2012. More information can be found at http://appcampus.aalto.fi/.About NokiaNokia is a global leader in mobile communications whose products have become an integral part of the lives of people around the world. Every day, more than 1.3 billion people use their Nokia to capture and share experiences, access information, find their way or simply to speak to one another. Nokia's technological and design innovations have made its brand one of the most recognized in the world. For more information, visit http://www.nokia.com/about-nokia.About the Aalto University Center for EntrepreneurshipThe Aalto Center for Entrepreneurship (ACE) at Aalto University, Finland, offers innovation, commercialization, and start-up services for Aalto University res
earchers, students and other stakeholders. In addition, we facilitate innovation and growth entrepreneurship by co-creating research and education of these areas across all the Aalto schools. ACE partially funds and participates in the award-winning Aalto Venture Garage and Startup Sauna open source seed accelerator. For more information, visit http://www.aalto.fi/ and http://ace.aalto.fi/.About MicrosoftFounded in 1975, Microsoft (Nasdaq: MSFT) is the worldwide leader in software, services and solutions that help people and businesses realise their full potential.About Microsoft EMEA (Europe, Middle East and Africa)Microsoft has operated in EMEA since 1982. In the region Microsoft employs more than 16,000 people in over 64 subsidiaries, delivering products and services in more than 139 countries and territories.This material is for informational purposes only. Microsoft Corp disclaims all warranties and conditions with regard to use of the material for other purposes. Microsoft Corp shall not, at any time, be liable for any special, direct, indirect or consequential damages, whether in an action of contract, negligence or other action arising out of or in connection with the use or performance of the material. Nothing herein should be construed as constituting any kind of warranty.
Monday, March 5, 2012
con preghiera di divulgazione: Barry Harris, la leggenda del Jazz in concerto a Roma!
------------------------------------------
Barry Harris, uno dei più grandi artisti della musica Jazz a livello mondiale, considerato il miglior interprete della musica di Bud Powell, Tadd Dameron, Thelenious Monk e che per più di mezzo secolo ha suonato con i giganti del jazz, tra cui: Dizzy Gillespie, Miles Davis, Dexter Gordon e Coleman Hawkins, sarà a Roma per un esclusivo concerto al Felt Music Club
Un'incredibile concerto accompagnato da Luca Pisani al Contrabbassoe e da Oreste Soldano alla batteria, amanti del Jazz e musicisti avranno l'occasione di ascoltare il celebre musicista dal vivo, ascoltando e vedendo chi ha contribuito personalmente alla storia della musica jazz.
Barry Harris non è solo un grande musicista, ma è ritenuto anche uno dei più autorevoli insegnanti del Jazz, durante l'anno, viaggia in tutto il mondo per condividere la sua esperienza con i suoi allievi. Il suo personale metodo d'insegnamento costituisce da decenni una profonda fonte d'ispirazione, consentendo a studenti di differenti livelli di partecipare alla stessa classe, grazie alla sua esperienza e straordinaria capacità comunicativa.
Barry Harris trio, al Felt Music Club di Roma il 23 Marzo
Inizio Concerto ore 21:00
Ingresso euro 15.00
Info e Prenotazioni
Felt Music Club – locale per eventi e musica dal vivo
Email: info@feltmusic.it
Tel: 06 491978
web promotion and community management
myPressLab – www.mypresslab.com – the social media expert
email: comunicati@mypresslab.com
mob. 345.160.299.4
Un saluto dalla redazione di myPressLab
Visita la nostra pagina Facebook! www.facebook.com/socialmediaexpert.italia
Seguici su Twitter! www.twitter.com/mypresslab
skype: mypresslab
msn: mypresslab@live.it
mob. 345.160.29.94
www.mypresslab.com - the Social Media Expert
----------
Ai sensi del D.lgs n. 196 del 30.06.03 (Codice Privacy) si precisa che le informazioni contenute in questo messaggio sono riservate e ad uso esclusivo del destinatario. Qualora il messaggio in parola Le fosse pervenuto per errore, La preghiamo di eliminarlo senza copiarlo e di non inoltrarlo a terzi, dandocene gentilmente comunicazione. Grazie
This message, for the D.lgs n. 196/30.06.03 (Privacy Code), may contain confidential and/or privileged information. If you are not the addressee or authorized to receive this for the addressee, you must not use, copy, disclose or take any action based on this message or any information herein. If you have received this message in error, please advise the sender immediately by reply e-mail and delete this message. Thank you for your cooperation.
Saturday, March 3, 2012
con preghiera di divulgazione: FLEURS DU MAL in concerto al Felt Music Club di Roma
http://www.mypresslab.com/blog/fleurs-du-mal-in-concerto-al-felt-music-club-di-roma.html
--
--------------------------------------------------------
FLEURS DU MAL in concerto al Felt Music Club di Roma
Roma, 9 Marzo 2012, i Fleurs Du Mal, nota band capitolina, ospiti del Felt Music Club (www.feltmusic.it), il locale interamente dedicato alla musica dal vivo nel cuore dello storico quartiere di San Lorenzo. Inizio concerto ore 22,30
FLEURS DU MAL info: http://www.myspace.com/fleursdumal2001
I FLEURS DU MAL tornano in concerto con la nuova formazione a 5 elementi, e proporranno dal vivo il loro repertorio di Rock mescolato al Blues, Swing, Funky, Latin-Rock, con testi in inglese, italiano e spagnolo. In scaletta diversi brani tratti dal CD "LOST & FOUND" (2008-Blond Records), alcuni brani inedit e naturalmente, non mancheranno i brani più famosi tratti dai precendenti album. Interessante sarà ascaltora i Fleursd du Mal con l'inserimento di un sax in aggiunta alla formazione precedente.
Brevi Note Biografiche
Il "LOST & FOUND Tour" che presenta dal vivo il CD "Lost & Found" ha toccato: Roma, Milano, Firenze, Bologna, Reggio Emilia, Perugia, Sorano(Gr), Vasto (Chieti), L'Aquila, Viterbo, Frosinone, "Liri Blues Festival-2010", Marino(Rm), Cagliari, Sassari, Nuoro, Olbia, Oristano (e varie altre localita' della Sardegna), Bellinzona(Svizzera) e 20 concerti in Olanda (tra i quali i prestigiosi "Festival Bevrjidings 5 Mei"-Wageningen-2008 http://www.4en5meiwageningen.nl, "Festival BeaPop"-2008 http://www.beapop.nl/ ,la "Home of the Blues of Amsterdam "Maloe Melo"-2008,2009e 2010 - http://www.maloemelo.com/, il prestigioso "De Spieghel" di Groningen-2009 e 2010 - http://www.jazzcafedespieghel.nl/, il grande "Willemeen" di Arnhem http://www.willemeen.nl/, e il "Het Blues Cafe'" di Apeldoorn http://www.bluescafe.nl).
FLEURS DU MAL Info line: 339-8148444
I FLEURS DU MAL sono:
STEFANO 'IGUANA'- Voce,Chitarra,Slide,armonica.
GRAZIELLA OLIVIERI-Sax Tenore.
ROBERTO CRUCIANI-Basso,cori.
DAVIDE MICCINILLI-Batteria.
CLEMENTE VERDICCHIO-Sax Contralto
Info e Contatti
INgresso Gratuito con Tessera (5 euro)
Felt Music Club
via degli ausoni 84
tel 06 491978
email info@feltmusic.it
community management and web promotion
myPressLab.com
email: comunicati@mypresslab.com
mob. 345 1602994
skype: mypresslab
Un saluto dalla redazione di myPressLab
Visita la nostra pagina Facebook! www.facebook.com/socialmediaexpert.italia
Seguici su Twitter! www.twitter.com/mypresslab
skype: mypresslab
msn: mypresslab@live.it
mob. 345.160.29.94
www.mypresslab.com - the Social Media Expert
----------
Ai sensi del D.lgs n. 196 del 30.06.03 (Codice Privacy) si precisa che le informazioni contenute in questo messaggio sono riservate e ad uso esclusivo del destinatario. Qualora il messaggio in parola Le fosse pervenuto per errore, La preghiamo di eliminarlo senza copiarlo e di non inoltrarlo a terzi, dandocene gentilmente comunicazione. Grazie
This message, for the D.lgs n. 196/30.06.03 (Privacy Code), may contain confidential and/or privileged information. If you are not the addressee or authorized to receive this for the addressee, you must not use, copy, disclose or take any action based on this message or any information herein. If you have received this message in error, please advise the sender immediately by reply e-mail and delete this message. Thank you for your cooperation.
Subscribe to:
Posts (Atom)
